Ennoble IP (EIP)’s Post

INPATCOM – Guess this Acronym? Post 1 India’s Patent Paradox: Innovating But Not Commercializing? India is a hub of innovation, consistently ranking among the top nations for patent filings. Yet, a significant challenge persists: low rates of patent commercialization. Despite breakthroughs in sectors like technology, pharmaceuticals, and green energy, the journey from innovation to market seems riddled with roadblocks. Some key questions: 1️⃣ Are we lacking robust industry-academia partnerships? 2️⃣ Is the funding ecosystem for commercialization underdeveloped? 3️⃣ Are innovators facing a gap in business expertise or market access? In my next post, I’ll dive into potential solutions to these challenges. But first, I want to hear from you! What, in your opinion, is the biggest reason for India’s struggles in patent commercialization? Let’s start a conversation—drop your thoughts in the comments below! #Innovation #Patents #India #Commercialization #StartupEcosystem #INPATCOM

𝐉𝐨𝐢𝐧 𝐔𝐬 𝐟𝐨𝐫 𝐚𝐧 𝐄𝐱𝐜𝐥𝐮𝐬𝐢𝐯𝐞 𝐈𝐧𝐝𝐮𝐬𝐭𝐫𝐲 𝐒𝐲𝐦𝐩𝐨𝐬𝐢𝐮𝐦 "𝐌𝐚𝐬𝐭𝐞𝐫𝐢𝐧𝐠 𝐂𝐨𝐧𝐭𝐢𝐧𝐮𝐨𝐮𝐬 𝐌𝐚𝐧𝐮𝐟𝐚𝐜𝐭𝐮𝐫𝐢𝐧𝐠 𝐚𝐧𝐝 𝐌𝐨𝐝𝐮𝐥𝐚𝐫 𝐏𝐥𝐚𝐧𝐭 𝐒𝐨𝐥𝐮𝐭𝐢𝐨𝐧𝐬 𝐟𝐨𝐫 𝐓𝐨𝐦𝐨𝐫𝐫𝐨𝐰'𝐬 𝐇𝐢𝐠𝐡-𝐐𝐮𝐚𝐥𝐢𝐭𝐲 𝐌𝐞𝐝𝐢𝐜𝐢𝐧𝐞𝐬." On 𝐌𝐚𝐫𝐜𝐡 𝟔, 𝟐𝟎𝟐𝟓 this symposium is organised for 𝐂𝐌𝐎’𝐬 , 𝐩𝐡𝐚𝐫𝐦𝐚 and 𝐟𝐢𝐧𝐞 𝐜𝐡𝐞𝐦𝐢𝐜𝐚𝐥𝐬 𝐜𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬. To ensure your spot or for more details, email us at 𝐦𝐚𝐫𝐤𝐞𝐭𝐢𝐧𝐠@𝐳𝐞𝐭𝐨𝐧.𝐧𝐥 𝐖𝐡𝐚𝐭 𝐭𝐨 𝐄𝐱𝐩𝐞𝐜𝐭: Gain valuable 𝐢𝐧𝐬𝐢𝐠𝐡𝐭𝐬 from industry leaders on: 𝐓𝐡𝐞 𝐄𝐯𝐨𝐥𝐮𝐭𝐢𝐨𝐧 𝐨𝐟 𝐌𝐨𝐝𝐮𝐥𝐚𝐫 𝐀𝐩𝐩𝐫𝐨𝐚𝐜𝐡𝐞𝐬: From past to future. 𝐅𝐥𝐞𝐱𝐢𝐛𝐢𝐥𝐢𝐭𝐲 & 𝐂𝐨𝐥𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐢𝐨𝐧: Learn how to create adaptable manufacturing processes and benefit from shared experiences. 𝐎𝐯𝐞𝐫𝐜𝐨𝐦𝐢𝐧𝐠 𝐋𝐢𝐦𝐢𝐭𝐚𝐭𝐢𝐨𝐧𝐬: Solutions for tackling challenges in continuous manufacturing. 𝐒𝐭𝐚𝐧𝐝𝐚𝐫𝐝𝐢𝐳𝐞𝐝 𝐄𝐧𝐠𝐢𝐧𝐞𝐞𝐫𝐢𝐧𝐠: Implementing modular, standardized automation solutions (e.g., MTP). 𝐎𝐩𝐩𝐨𝐫𝐭𝐮𝐧𝐢𝐭𝐢𝐞𝐬 & 𝐂𝐡𝐚𝐥𝐥𝐞𝐧𝐠𝐞𝐬: Opportunities and challenges in continuous manufacturing in both pharma and non-pharma sectors, including 24/7 operation challenges and staffing resources, and plug and play in GAMP environments: challenges faced and solutions 𝐒𝐡𝐨𝐩 𝐓𝐨𝐮𝐫: See our ongoing projects at Zeton BV, including the 𝐟𝐮𝐥𝐥𝐲 𝐨𝐩𝐞𝐫𝐚𝐭𝐢𝐨𝐧𝐚𝐥 𝐂𝐨𝐧𝐭𝐢𝐔𝐧𝐢𝐭𝐲® 𝐩𝐫𝐨𝐜𝐞𝐬𝐬 𝐬𝐲𝐬𝐭𝐞𝐦! 𝐂𝐨𝐧𝐟𝐢𝐫𝐦𝐞𝐝 𝐒𝐩𝐞𝐚𝐤𝐞𝐫𝐬: 𝐆𝐚𝐫𝐞𝐭𝐡 𝐀𝐥𝐟𝐨𝐫𝐝, AstraZeneca 𝐃𝐚𝐯𝐢𝐝 𝐋𝐢𝐧𝐝𝐞𝐫, F. Hoffmann - La Roche Ltd. 𝐑𝐢𝐜𝐤 𝐒𝐩𝐞𝐧𝐜𝐞𝐫, Eli Lilly 𝐆𝐚𝐛𝐫𝐢𝐞𝐥 𝐋𝐨𝐡, A*STAR Institute of Sustainability for Chemicals, Energy & Environment (ISCE2) 𝐁𝐞𝐫𝐭 𝐌𝐞𝐭𝐭𝐞𝐧, Ajinomoto Bio-Pharma Services 𝐋𝐨𝐜𝐚𝐭𝐢𝐨𝐧: University of Twente, Building Vrijhof, Enschede, the Netherlands   𝐑𝐞𝐠𝐢𝐬𝐭𝐫𝐚𝐭𝐢𝐨𝐧 𝐅𝐞𝐞: Symposium registration fee amounts to €90. The net revenue will be donated to the Princess Máxima Center Foundation.   𝐋𝐢𝐦𝐢𝐭𝐞𝐝 𝐒𝐞𝐚𝐭𝐬 𝐀𝐯𝐚𝐢𝐥𝐚𝐛𝐥𝐞 This symposium is designed specifically for 𝐂𝐌𝐎𝐬, 𝐩𝐡𝐚𝐫𝐦𝐚 𝐩𝐫𝐨𝐝𝐮𝐜𝐞𝐫𝐬, 𝐚𝐧𝐝 𝐟𝐢𝐧𝐞 𝐜𝐡𝐞𝐦𝐢𝐜𝐚𝐥 𝐦𝐚𝐧𝐮𝐟𝐚𝐜𝐭𝐮𝐫𝐞𝐫𝐬. To ensure your spot or for more details, email us at 𝐦𝐚𝐫𝐤𝐞𝐭𝐢𝐧𝐠@𝐳𝐞𝐭𝐨𝐧.𝐧𝐥 Don’t miss this opportunity to connect with leading experts and shape the future of modular and continuous manufacturing! 𝐃𝐞𝐚𝐝𝐥𝐢𝐧𝐞 𝐟𝐨𝐫 𝐫𝐞𝐠𝐢𝐬𝐭𝐫𝐚𝐭𝐢𝐨𝐧: 𝐉𝐚𝐧𝐮𝐚𝐫𝐲 𝟑𝟏, 𝟐𝟎𝟐𝟓 We look forward to welcoming you on March 6!

In Japanese there are two words: 改 kai - change, revision 善 zen - virtue, goodness Kaizen is the practice of making continuous improvements. Most notably used in manufacturing it is also a powerful tool for the world of clinical trials. Read more: https://lnkd.in/e22YZX8g #kaizen #lean #clinicaltrials #clinicalresearch #biotech #innovation

Reflections on BioProcess UK 2024 - An insightful event that showcased both optimism and some ongoing challenges for our sector. ✨ Highlights included: * Exciting new facilities and licenses announced by FUJIFILM Diosynth Biotechnologies and eXmoor Pharma, showcasing the sector's ambition. * Leadership on sustainability from MMIP and BioIndustry Association (BIA) members and practical case studies such as CPI’s innovative intelligent cleanroom control system. 🌱 * The Dragons' Den pitches—a fantastic showcase of emerging innovation. CPI is already collaborating with many of these promising companies! * Congratulations to Professor Suzanne Farid on receiving the Peter Dunnill Award for her outstanding contributions to bioprocessing. 🎉👏 💡 Despite the optimism, challenges remain: * Investment is still slow, and many businesses haven’t yet seen a full recovery. 📉 * Funding pressures for early-stage companies make it hard to prioritise manufacturability and balance work to meet the needs of investors, regulatory and payers - all key to market success. ⚖ It was reassuring to sense a collective relief across the sector at a relatively stable funding and policy environment, even amidst a change in government. I think we would all like to focus more on action now, rather than getting bogged down in policy documents. As ever, I'm convinced collaboration is the key to overcoming these hurdles. What were your takeaways from the event? Brendan Fish Julie Anderson Philip Probert Zoe Arnott Jessica Sayers Kirsty Skeene Alan Robertson Dave Tudor #bioProcessUK #LifeSciences #Biomanufacturing #Sustainability #Innovation #RegulatoryAffairs #EmergingTechnologies #Collaboration #UKBiotech #PolicyAndFunding

In 2015, LyoHUB received a grant from the National Institute of Standards and Technology (NIST) to form a new lyophilization consortium and construct a technology roadmap. After two years and the input from over 100 lyophilization experts, LyoHUB published the Lyophilization Technology Roadmap. Check out the 2017 roadmap here https://lnkd.in/d8jHMVSY. This 2017 roadmap identifies top needs such as improved scale-up processes, better understanding of relationship between process variable & product quality, workforce development etc. Over the past 10 years, LyoHUB has responded to the needs identified in this roadmap by publishing 7 best practice papers, conducting science-advancing research and providing excellent training opportunities. On October 4, 2024, LyoHUB will launch its newest roadmap Lyo2040: Lyophilization and Freeze-Thaw Technology Roadmap for Pharma/Biotech Manufacturing. Watch our website for more information! https://lnkd.in/g9wVdxGa #Lyophilization #FreezeDrying #Innovation #LyoHUB #PurdueUniversity #PharmaTech #Biotech

Debut is tremendously honored to be the first company to receive the Department of Defense’s award for the Distributed Bioindustrial Manufacturing Program aimed at expanding the domestic supply of ingredients and materials for US supply chains and bolstering the bioindustrial manufacturing base. As part of the award, Debut will receive $2M to produce business and technical plans outlining construction of a domestic bioindustrial manufacturing facility. If (and when!) successful, Debut can receive a follow-on award of up to $100M to build a US-based bioindustrial manufacturing facility. “To be the first company to receive this award is incredibly meaningful, as is the fact that our teams and scaled advanced biomanufacturing processes are deemed best-in-class,” said Debut’s Founder and CEO Joshua Britton. “As we continue to pioneer biotech in beauty, this award inspires our work further still in leading the industry’s transition to biotechnology and securing vital US supply chains.” Click here to read the Department of Defense’s press release: https://shorturl.at/UDN3X #biotechnology #biomanufacturing #bioeconomy #biotechbeauty #futureofbeauty

Ingredient transparency is paramount

#Qora71Investments: Latest investment by Qora71 into Hub71-based Basetwo AI as part of $11.5m Series A alongside AVP, Glasswing Ventures, Deloitte Ventures Canada, Global Brain Corporation, SHIMADZU CORPORATION, Chiyoda Corporation. Basetwo Physics AI platform combines fundamental chemical engineering with AI to optimize pharmaceutical and chemical manufacturing processes. This results in 40% improvement in cycle times and raw material usage and 25% improvement in product quality. Founded by Thouheed Abdul Gaffoor Thamjeeth Abdul Gaffoor Tawfeeq Abdul Gaffoor Kiefer Eaton Marks 50th technology company in which Qora71 syndicate members are investors, board members or advisors, including 16 ventures who are Hub71 based. Other recent investments include autone, BioSapien, zypl.ai, and AlGooru | القورو, and more to be announced shortly.

The BIOSECURE Act In January 2024, the US senate house introduced a version of BIOSECURE Act to be discussed with committee which proposes to prohibit federal agencies from procuring, purchasing, or obtaining biotechnology equipment or services from a biotechnology company that is controlled or operated on behalf of a foreign adversary, most notably China (1). This is explicitly aimed at those entities which are directly operated Chinese companies or those companies which have indirect interest from Chinese government such as BGI, MGI, Complete Genomics, and WuXi AppTec that were explicitly named, and the government will have full authority in future to name other flagged entities as well. Currently, the act is already passed through the House of Representatives with a substantial majority and is expected to be passed by the senate soon to become a law (2). But what does it mean for Biotech and pharma, particularly smaller firms? Large pharma may not feel the need to jump on sudden thinking wagon as lot of their operations take place in-house across the globe. However, smaller biotech and pharma firms which contract heavily with CDMOs especially with established ones such as WuxiApp Tec are finding it difficult to plan ahead. Although, the act provides provision to sustain contracts between US firms and Chinese contract development and manufacturing organizations (CDMOs) until 2032 but do companies see this is as a viable timeline? According to an interview in Bioprocess International with Andrew Harmon, a senior consultant at the Latham Biopharm Group, the 8 years' timeline is not sufficient from industry's point-of-view to make all transitions for their signed deals, tech transfer, make organizational changes etc. Now, is the right time for small biotech and pharma to start thinking about their strategic developmental plans as this is eventual reality and it is important to start thinking whom to look for and for what. Sources: 1. U.S. House of Representatives Pass BIOSECURE, Cloud Access and Multiple Other Bills Targeting China, Simpson Thatcher Sep 2024; 2. Size matters when navigating BIOSECURE, says consultant, Bioprocess International 2024 #Biotechnology #Biosecurity #Outsourcing #Federalact #policy #regulatory

🙌 Your ally in innovation 🙌 📦 Developing a new product is exhilarating, but how do you navigate the path from idea to innovative product? ⏩ Let QIAGEN guide the way with over 40 years of experience in biotechnology with established processes for speed and quality: https://lnkd.in/gqB5Ns2M #QIAGEN #StrategicPartnership #AccelerateYourInnovation